Tumour necrosis factor (TNF) inhibitor therapy in Susac's syndrome

T. A. Hardy; R. J. Garsia; G. M. Halmagyi; S. J. G. Lewis; B. Harrisberg; M. J. Fulham; M. H. Barnett

doi:10.1016/j.jns.2010.11.016

Tumour necrosis factor (TNF) inhibitor therapy in Susac's syndrome

T. A. Hardy, R. J. Garsia, G. M. Halmagyi, S. J. G. Lewis, B. Harrisberg, M. J. Fulham, M. H. Barnett

Research output: Contribution to journal › Article › peer-review

34 Citations (Scopus)

Abstract

Susac's syndrome is the clinical triad of encephalopathy, branch retinal artery occlusions and sensorineural hearing loss (Susac 1994) [1]. It occurs predominantly in young females and is believed to be an immune-mediated endotheliopathy of small vessels of the brain, retina and cochlea (Neumayer et al. 2009) [2]. Early, aggressive, and sustained immunosuppressive therapy has been recommended for Susac's syndrome and anecdotal evidence has suggested a therapeutic role for monoclonal antibodies (Rennebohm et al. 2008, Lee and Amezcua 2009) [3,4]. We report a case of Susac's syndrome in which the patient improved immediately after tumour necrosis factor (TNF) inhibition with the monoclonal antibody, infliximab.

Original language	English
Pages (from-to)	126-128
Number of pages	3
Journal	Journal of the Neurological Sciences
Volume	302
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jns.2010.11.016
Publication status	Published - 15 Mar 2011
Externally published	Yes

Keywords

Corpus callosum
Monoclonal antibody
PET
Pregnancy
Susac's syndrome
TNF-inhibitor

Access to Document

10.1016/j.jns.2010.11.016

Cite this

@article{eadf2d26cb564d3cbee024cdc343e4ed,

title = "Tumour necrosis factor (TNF) inhibitor therapy in Susac's syndrome",

abstract = "Susac's syndrome is the clinical triad of encephalopathy, branch retinal artery occlusions and sensorineural hearing loss (Susac 1994) [1]. It occurs predominantly in young females and is believed to be an immune-mediated endotheliopathy of small vessels of the brain, retina and cochlea (Neumayer et al. 2009) [2]. Early, aggressive, and sustained immunosuppressive therapy has been recommended for Susac's syndrome and anecdotal evidence has suggested a therapeutic role for monoclonal antibodies (Rennebohm et al. 2008, Lee and Amezcua 2009) [3,4]. We report a case of Susac's syndrome in which the patient improved immediately after tumour necrosis factor (TNF) inhibition with the monoclonal antibody, infliximab.",

keywords = "Corpus callosum, Monoclonal antibody, PET, Pregnancy, Susac's syndrome, TNF-inhibitor",

author = "Hardy, {T. A.} and Garsia, {R. J.} and Halmagyi, {G. M.} and Lewis, {S. J. G.} and B. Harrisberg and Fulham, {M. J.} and Barnett, {M. H.}",

year = "2011",

month = mar,

day = "15",

doi = "10.1016/j.jns.2010.11.016",

language = "English",

volume = "302",

pages = "126--128",

journal = "Journal of the Neurological Sciences",

issn = "0022-510X",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Tumour necrosis factor (TNF) inhibitor therapy in Susac's syndrome

AU - Hardy, T. A.

AU - Garsia, R. J.

AU - Halmagyi, G. M.

AU - Lewis, S. J. G.

AU - Harrisberg, B.

AU - Fulham, M. J.

AU - Barnett, M. H.

PY - 2011/3/15

Y1 - 2011/3/15

N2 - Susac's syndrome is the clinical triad of encephalopathy, branch retinal artery occlusions and sensorineural hearing loss (Susac 1994) [1]. It occurs predominantly in young females and is believed to be an immune-mediated endotheliopathy of small vessels of the brain, retina and cochlea (Neumayer et al. 2009) [2]. Early, aggressive, and sustained immunosuppressive therapy has been recommended for Susac's syndrome and anecdotal evidence has suggested a therapeutic role for monoclonal antibodies (Rennebohm et al. 2008, Lee and Amezcua 2009) [3,4]. We report a case of Susac's syndrome in which the patient improved immediately after tumour necrosis factor (TNF) inhibition with the monoclonal antibody, infliximab.

AB - Susac's syndrome is the clinical triad of encephalopathy, branch retinal artery occlusions and sensorineural hearing loss (Susac 1994) [1]. It occurs predominantly in young females and is believed to be an immune-mediated endotheliopathy of small vessels of the brain, retina and cochlea (Neumayer et al. 2009) [2]. Early, aggressive, and sustained immunosuppressive therapy has been recommended for Susac's syndrome and anecdotal evidence has suggested a therapeutic role for monoclonal antibodies (Rennebohm et al. 2008, Lee and Amezcua 2009) [3,4]. We report a case of Susac's syndrome in which the patient improved immediately after tumour necrosis factor (TNF) inhibition with the monoclonal antibody, infliximab.

KW - Corpus callosum

KW - Monoclonal antibody

KW - PET

KW - Pregnancy

KW - Susac's syndrome

KW - TNF-inhibitor

UR - http://www.scopus.com/inward/record.url?scp=79951512184&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2010.11.016

DO - 10.1016/j.jns.2010.11.016

M3 - Article

C2 - 21167503

AN - SCOPUS:79951512184

SN - 0022-510X

VL - 302

SP - 126

EP - 128

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

IS - 1-2

ER -

Tumour necrosis factor (TNF) inhibitor therapy in Susac's syndrome

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this